MedPath
HSA Approval

DBL DACARBAZINE FOR INJECTION 200 mg

SIN06424P

DBL DACARBAZINE FOR INJECTION 200 mg

DBL DACARBAZINE FOR INJECTION 200 mg

July 8, 1991

PFIZER PRIVATE LIMITED

PFIZER PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPFIZER PRIVATE LIMITED
Licence HolderPFIZER PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAVENOUS

Medical Information

L01AX04

dacarbazine

Manufacturer Information

PFIZER PRIVATE LIMITED

Zydus Hospira Oncology Private Limited (ZHOPL)

Active Ingredients

DACARBAZINE

200 mg/vial

Dacarbazine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DBL DACARBAZINE FOR INJECTION 200 mg - HSA Approval | MedPath